ArticleCureus2024
Can Serum Gamma-Glutamyl Transferase Predict All-Cause Mortality in Hypertensive Patients?
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Role of ChREBP-PPARα-FGF21 Axis in Metabolic Dysfunction of MASLD.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction In this investigation, the focus was on exploring the connection between serum gamma-glutamyl transferase (GGT), a vital element that influences health and mortality in relation to aging, and all-cause mortality. The study was conducted using a follow-up approach at eight- and 20-year intervals. Methods The study involved 1,101 female participants, with an average age of 69 years (± 9), and 916 male participants, with an average age of 67 years (± 11), who were all diagnosed with hypertension. These individuals were drawn from the Nomura cohort study, which consisted of two separate cohorts: the initial cohort established in 2002 and the subsequent cohort in 2014. We used a Cox proportional hazards model to calculate the hazard ratios (HRs), adjusted for multiple variables, for mortality risk from the initial health examination until the conclusion of the follow-up periods. Results The study followed the participants for a median period of 13.9 years (interquartile range: 8.5-20.2 years). During this follow-up period, 716 deaths were recorded in this population (360 in men and 356 in women), resulting in a mortality rate of 25.5 deaths per 1,000 person-years. Male participants categorized with serum GGT levels ranging from 42 to 86 IU/L showed a 64% increased risk of all-cause mortality (HR: 1.64; 95% confidence interval (CI): 1.11-2.40), while those with GGT levels of 87 IU/L or higher exhibited a 93% elevated risk (HR: 1.93; 95% CI: 1.18-3.16) compared to individuals with GGT levels below 19 IU/L. The association between higher GGT levels and increased all-cause mortality was more evident in men than in women, with a significant interaction between gender and baseline serum GGT (p = 0.020). Conclusions Our findings suggest a notable correlation between irregular GGT levels and the overall mortality rate among Japanese individuals with hypertension living in community settings. Notably, especially in older males, GGT activity turns out to be a critical biomarker for predicting long-term survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.